The Case Analysis Of Epidermal Growth Factor Receptor-targeted Therapies Combined With Chemoradiotherapy In Esophageal Squamous Cell Carcinoma And Literature Review

Objective: Esophageal cancer is one of the malignant tumors threatening human health seriously.The incidence and mortality of esophageal cancer rank the sixth and fourth in China,respectively,with squamous carcinoma accounting for 90%.The current standard treatment for inoperable esophageal squamous cell carcinoma(ESCC)is concurrent chemoradiotherapy,but the 5-year survival rate is low.Thus,it needs to develop new treatments to improve this outcome.In recent years,molecular targeted therapy has become an new direction in cancer therapy and has shown good efficacy in various tumors.Some of the molecular targeted drugs combined with radiotherapy or chemoradiotherapy for ESCC have been carried out in a number of clinical trials,especially those targeting epidermal growth factor receptor(EGFR),including anti-EGFR monoclonal antibodies,such as cetuximab and nimotuzumab,and EGFR-tyrosine kinase inhibitor,such as gefitinib and erlotinib.Effective screening of the dominant population of EGFR-targeted drugs is one of the major problems currently facing.This article describes a case of inoperable esophageal squamous cell carcinoma admitted to our department,and analyzes the safety and efficacy of the EGFR-targeted drugs combined with concurrent chemoradiotherapy.Method: Retrospectively analysis 1 case of inoperable esophageal squamous cell carcinoma treated with cetuximab combined with concurrent chemoradiotherapy in our department.At the same time,we reviewed the relevant literatures at home and abroad,then summarized the safety,efficacy and biomarker development of EGFR-targeted drugs combined with concurrent chemoradiotherapy,so as to provide assistance for the treatment of esophageal squamous cell carcinoma.Result: The patient was treated with cetuximab in combination with concurrent chemoradiotherapy.The condition was stable after treatment.Regular review and follow-up showed no recurrence or metastasis,and long-term survival was achieved.Conclusion: This case analysis shows that some patients with esophageal squamous cell carcinoma can benefit from the clinical treatment of cetuximab combined with concurrent chemoradiotherapy,and in the future,it is necessary to find suitable biomarkers for predictable therapeutic effects to screen out the population benefiting from EGFR-targeted drugs and provide more effective individualized treatment.